Literature DB >> 14981647

Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach.

Nicola J Cooper1, Alex J Sutton, Keith R Abrams, David Turner, Allan Wailoo.   

Abstract

Decision analytical models are widely used in economic evaluation of health care interventions with the objective of generating valuable information to assist health policy decision-makers to allocate scarce health care resources efficiently. The whole decision modelling process can be summarised in four stages: (i) a systematic review of the relevant data (including meta-analyses), (ii) estimation of all inputs into the model (including effectiveness, transition probabilities and costs), (iii) sensitivity analysis for data and model specifications, and (iv) evaluation of the model. The aim of this paper is to demonstrate how the individual components of decision modelling, outlined above, may be addressed simultaneously in one coherent Bayesian model (sometimes known as a comprehensive decision analytical model) and evaluated using Markov Chain Monte Carlo simulation implemented in the specialist software WinBUGS. To illustrate the method described, it is applied to two illustrative examples: (1) The prophylactic use of neurominidase inhibitors for the prevention of influenza. (2) The use of taxanes for the second-line treatment of advanced breast cancer. The advantages of integrating the four stages outlined into one comprehensive decision analytical model, compared to the conventional 'two-stage' approach, are discussed. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981647     DOI: 10.1002/hec.804

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  26 in total

1.  Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.

Authors:  Christopher H Jackson; Mark Jit; Linda D Sharples; Daniela De Angelis
Journal:  Med Decis Making       Date:  2013-07-25       Impact factor: 2.583

Review 2.  Assessing the effectiveness of primary angioplasty compared with thrombolysis and its relationship to time delay: a Bayesian evidence synthesis.

Authors:  Christian Asseburg; Yolanda Bravo Vergel; Stephen Palmer; Elisabeth Fenwick; Mark de Belder; Keith R Abrams; Mark Sculpher
Journal:  Heart       Date:  2007-02-03       Impact factor: 5.994

Review 3.  The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.

Authors:  Grant H Skrepnek
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 4.  Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis.

Authors:  Yolanda Bravo Vergel; Stephen Palmer; Christian Asseburg; Elisabeth Fenwick; Mark de Belder; Keith Abrams; Mark Sculpher
Journal:  Heart       Date:  2007-08-23       Impact factor: 5.994

5.  A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes.

Authors:  Pepijn Vemer; Maiwenn J Al; Mark Oppe; Maureen P M H Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

6.  Continuous time simulation and discretized models for cost-effectiveness analysis.

Authors:  Marta O Soares; Luísa Canto E Castro
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

7.  Network vs. pairwise meta-analyses: a case study of the impact of an evidence-synthesis paradigm on value of information outcomes.

Authors:  Zafar Zafari; Kristian Thorlund; J Mark FitzGerald; Carlo A Marra; Mohsen Sadatsafavi
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

Review 8.  'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data.

Authors:  Andrea Manca; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

9.  Structural and parameter uncertainty in Bayesian cost-effectiveness models.

Authors:  Christopher H Jackson; Linda D Sharples; Simon G Thompson
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2010-03       Impact factor: 1.864

10.  Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics.

Authors:  Kimbach Tran Carpiuc; Gianantonio Rosti; Fausto Castagnetti; Maarten Treur; Jennifer Stephens
Journal:  Onco Targets Ther       Date:  2010-10-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.